HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Crosscope Dx is a workflow integrated vendor-agnostic digital pathology platform that offers end-to-end digital pathology solutions with advanced workflow features
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
With close to 2,800 highly skilled employees, GITC is now one of the largest technology centres across the Life Sciences industry in the country
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Through this new set-up, the company intends to make available, affordable high-quality medical diagnostic imaging equipment across Tier 2, 3, and 4 towns in India
The plant is scheduled to come on stream in September 2024
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
Fujifilm has been at the forefront of medical imaging and healthcare informatics. It’s developing new AI platforms to address medical challenges. Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India gives us an insight in an interview with Thomas C. Thottathil, Editor, indianpharmapost.com
Subscribe To Our Newsletter & Stay Updated